BIVI Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States...

Stats
Šios dienos apimtis	312 670
Vidutinė apimtis	2.59M
Rinkos kapitalizacija	26.63M
EPS	$0 ( 2024-02-09 )
Kita pelno data	( $-0.330 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.410
ATR14	$0.00300 (0.62%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-04	Do Cuong V	Buy	10 000	Common stock
2024-03-04	Do Cuong V	Buy	5 000	Warrants (right to buy)
2023-12-11	Kim Joanne Wendy	Buy	5 000	Common Stock
2023-11-09	Lang James Paul	Buy	93 500	Stock Option (right to buy)
2023-11-09	Gorlin Steve	Buy	46 358	Common Stock

INSIDER POWER
91.52
Last 94 transactions
Buy: 39 235 676 \| Sell: 4 917 434

Tūris Koreliacija

Ilgas: -0.03 (neutral)

Trumpas: -0.22 (neutral)

Signal:(48.226) Neutral

Biovie Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
IONM	0.843
CIDM	0.823
AACG	0.818
GAINL	0.807
CERC	0.806
AMRB	0.802

10 Labiausiai neigiamai susiję koreliacijos
DBX	-0.895
RMRM	-0.894
PCT	-0.882
PTC	-0.866
NOVT	-0.864
OPEN	-0.861
CVAC	-0.846
XP	-0.845
FTHM	-0.842
EXPI	-0.842

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Biovie Inc Koreliacija - Valiuta/Žaliavos

0.00
( neutral )

-0.01
( neutral )

Biovie Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-266 842 (0.00 %)
EPS:	$-1.550

FY	2023
Pajamos:	$0
Bruto pelnas:	$-266 842 (0.00 %)
EPS:	$-1.550

FY	2022
Pajamos:	$0
Bruto pelnas:	$-237 421 (0.00 %)
EPS:	$-0.920

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-10.50

Financial Reports:

No articles found.

Biovie Inc

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.